Cisplatin is the standard of care for pediatric solid tumors and is often associated with ototoxicity. It is estimated that about 60% of children on Cisplatin therapy develop irreversible ototoxicity, which manifests itself as hearing loss, sometimes accompanied by tinnitus.Fennec Pharmaceuticals Inc. (FENC) has developed a drug for the prevention of ototoxicity induced by Cisplatin chemotherapy in patients one month to less than 18 years of age with localized, non-metastatic, solid tumors.The drug candidate named Pedmark is under FDA priority review, with a decision expected on August 10, 2020.There is currently no established preventive agent for this hearing loss due to chemotherapy and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. If approved, Pedmark has the potential to prevent chemotherapy-induced hearing loss and be the first available agent approved for this condition.FENC closed Friday’s (Jul.24, 2020) trading at $8.68, down 0.91%.